David R. Epstein

David Epstein is  Chief Executive Officer at Seagen and a board member at Valo Health.  David is also a Director at the non-profit Three Opinions Foundation and Chairman of South Florida’s Pelican Harbor Seabird Station (PHSS).  PHSS is Miami’s premier native wildlife hospital dedicated to the rescue, rehabilitation, and release of sick, injured or orphaned brown pelicans, seabirds, and other native wildlife thus enabling future generations.

From early 2010 to mid 2016, David served as chief executive officer of Novartis Pharmaceuticals, a division of Novartis AG.  Previously, David started and led Novartis’ Oncology and Molecular Diagnostic units. Under his leadership the company’s oncology business grew to the second largest in the world.

David has more than 30 years of extensive drug development, deal making, commercialization and leadership experience on a global scale. Over the course of his career he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Afinitor, Cosentyx and Entresto.  His teams developed 3 Prix Galien award winning medicines and he has developed several CEOs. He was also recognized by FierceBiotech as one of the “25 most influential people in biopharma”.

Previous member Next member